Jamie Triccas

Professor Jamie Triccas is a Professor of Medical Microbiology and Theme Leader in the Infection, Immunity and Inflammation Theme at the University of Sydney’s School of Medical Sciences. He leads research programs in tuberculosis (TB) vaccine development, bacterial pathogenesis, and antimicrobial drug discovery. His work focuses on defining immunity to chronic bacterial pathogens like Mycobacterium tuberculosis, Pseudomonas aeruginosa, and Mycobacterium abscesses, alongside efforts to combat emerging threats such as SARS-CoV-2. He is part of the Sydney Infectious Diseases Institute and the Charles Perkins Centre, contributing to translational research with industry partners like Bharat Biotech and ExcellGene.

His research interests span vaccine design, host-pathogen interactions, and drug discovery, with a focus on novel adjuvants and immunotherapies. Key achievements include advancing TB vaccine candidates through international consortia and developing a SARS-CoV-2 vaccine consortium supported by CEPI. He also leads NIH-funded studies on TB adjuvants and immune correlates.

Recent studies highlight protective immune mechanisms against pulmonary infections, including IL-17A-driven T cell responses and lung-resident memory T cell generation. His team has discovered potent anti-tubercular compounds, such as bedaquiline analogues and metal-cyclam complexes, while patenting novel BCG-based vaccines (BCG-CYS).

Current projects include assessing BCG efficacy against non-tuberculous mycobacteria in cystic fibrosis and investigating correlates of protection in SARS-CoV-2 immunity. Collaborations span global networks, emphasizing precision medicine in TB management and microbial therapy for cancer.